In keeping with US Department of Health and Human Services Secretary Robert F Kennedy Jr’s promise to carry out the Department’s work with “radical transparency” and mitigate perceived industry influence and conflicts of interests, Food and Drug Administration (FDA) Commissioner Dr Martin Makary, has announced a policy directive.
This limits individuals employed at companies regulated by the FDA, such as drugmakers, from serving as official members on FDA advisory committees, where statutorily allowed. As part of this effort, the agency will prioritize and elevate the role of patients and caregivers, strengthening the voices of their communities.
The FDA uses its advisory committees to obtain independent expert advice and recommendations on scientific, technical, and policy decisions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze